<DOC>
	<DOCNO>NCT02049281</DOCNO>
	<brief_summary>This study evaluate thrice weekly dose vintafolide find maximum tolerable dose . The primary study hypothesis administration vintafolide participant advance solid tumor acceptable safety tolerability .</brief_summary>
	<brief_title>A Study Vintafolide ( MK-8109 ) Participants With Advanced Solid Tumor ( MK-8109-011 )</brief_title>
	<detailed_description />
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>Histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Chemotherapy , radiotherapy , biological therapy ( include monoclonal antibody ) within 4 week prior drug administration ( 6 week nitrosoureas mitomycin C ) recover adverse event due agent administer 4 week earlier Primary central nervous system ( CNS ) tumor Active CNS metastases and/or carcinomatous meningitis Known hypersensitivity component study therapy analog Recent history abdominal surgery peritonitis Bowel occlusion sub occlusion Prior abdominal pelvis radiation therapy radiation therapy &gt; 10 % bone marrow time past prior radiation therapy within last three year breast / sternum , head , neck Requires antifolate therapy Symptomatic ascites pleural effusion Prior stem cell bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>